SG11202006837XA - Dihydroindolizinone derivative - Google Patents

Dihydroindolizinone derivative

Info

Publication number
SG11202006837XA
SG11202006837XA SG11202006837XA SG11202006837XA SG11202006837XA SG 11202006837X A SG11202006837X A SG 11202006837XA SG 11202006837X A SG11202006837X A SG 11202006837XA SG 11202006837X A SG11202006837X A SG 11202006837XA SG 11202006837X A SG11202006837X A SG 11202006837XA
Authority
SG
Singapore
Prior art keywords
dihydroindolizinone
derivative
dihydroindolizinone derivative
Prior art date
Application number
SG11202006837XA
Inventor
Toshihiro Kiho
Tatsuya Yano
Satoshi Komoriya
Taisaku Tanaka
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of SG11202006837XA publication Critical patent/SG11202006837XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0676Pancreatic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37Digestive system
    • A61K35/39Pancreas; Islets of Langerhans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48Reproductive organs
    • A61K35/54Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70Enzymes
    • C12N2501/73Hydrolases (EC 3.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999Small molecules not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
SG11202006837XA 2018-01-18 2019-01-18 Dihydroindolizinone derivative SG11202006837XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018006269 2018-01-18
PCT/JP2019/001364 WO2019142883A1 (en) 2018-01-18 2019-01-18 Dihydroindolizinone derivative

Publications (1)

Publication Number Publication Date
SG11202006837XA true SG11202006837XA (en) 2020-08-28

Family

ID=67302218

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006837XA SG11202006837XA (en) 2018-01-18 2019-01-18 Dihydroindolizinone derivative

Country Status (12)

Country Link
US (1) US11530211B2 (en)
EP (1) EP3741757B1 (en)
JP (1) JP7359697B2 (en)
KR (1) KR20200110338A (en)
CN (1) CN111630052B (en)
AU (1) AU2019208634A1 (en)
CA (1) CA3088968C (en)
ES (1) ES2958118T3 (en)
IL (1) IL276125A (en)
SG (1) SG11202006837XA (en)
TW (1) TWI818948B (en)
WO (1) WO2019142883A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020309946A1 (en) * 2019-07-08 2022-03-03 Daiichi Sankyo Company, Limited Method for producing insulin-producing cell using dihydroindolizinone derivatives

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039059A1 (en) 2001-08-06 2005-02-09 Sanofi Aventis COMPOUND DERIVED FROM ACILAMINOTIAZOL, ITS USE, PROCEDURES TO PREPARE IT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, AND INTERMEDIARY COMPOUNDS
JP2003128551A (en) * 2001-08-15 2003-05-08 Sankyo Co Ltd New antidiabetic pharmaceutical composition
WO2007022506A2 (en) 2005-08-18 2007-02-22 University Of Massachusetts Methods and compositions for treating neurological disease
EP2650359B1 (en) 2006-03-02 2022-05-04 Viacyte, Inc. Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
CN102307871A (en) * 2008-12-08 2012-01-04 西特里斯药业公司 Isoindolinone and related analogs as sirtuin modulators
JP5938726B2 (en) 2010-10-28 2016-06-22 国立大学法人 熊本大学 Method and medium for improving differentiation induction efficiency of pluripotent stem cells
JPWO2012121168A1 (en) * 2011-03-04 2014-07-17 国立大学法人京都大学 Kinase inhibitor
WO2013163739A1 (en) 2012-04-30 2013-11-07 University Health Network METHODS AND COMPOSITIONS FOR GENERATING PANCREATIC PROGENITORS AND FUNCTIONAL BETA CELLS FROM hPSCs
JP2014161257A (en) 2013-02-22 2014-09-08 Univ Of Tokyo Method for preparing pancreatic langerhans islet from pluripotent stem cell
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US9796962B2 (en) 2013-08-07 2017-10-24 Kyoto University Method for generating pancreatic hormone-producing cells
DK3039122T3 (en) 2013-08-30 2019-09-30 Novo Nordisk As GENERATION OF ENDOCRINE PROGENITOR CELLS FROM HUMAN PLURIPOTENT STEM CELLS USING SMALL MOLECULES
JP6351018B2 (en) 2014-02-21 2018-07-04 国立大学法人 熊本大学 Stem cell differentiation induction method using amino acid composition modified medium, and medium kit containing the medium
JP6094516B2 (en) 2014-03-19 2017-03-15 三菱電機株式会社 Elevator equipment
EP3143127B1 (en) 2014-05-16 2021-07-14 Janssen Biotech, Inc. Use of small molecules to enhance mafa expression in pancreatic endocrine cells
JP6596708B2 (en) 2014-05-20 2019-10-30 国立大学法人東京工業大学 Method for inducing differentiation of insulin producing cells
RU2017105133A (en) * 2014-07-31 2018-08-28 Мерк Патент Гмбх INDOLYSINE DERIVATIVES THAT USE FOR NEURODEGENERATIVE DISEASES
US20160175363A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Methods for generating stem cell-derived beta cells and uses thereof
WO2016100898A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived b cells and uses thereof
WO2016100925A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College METHODS FOR GENERATING AUGMENTED STEM CELL-DERIVED β CELLS AND USES THEREOF
WO2016100909A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF
CN113234661A (en) 2014-12-18 2021-08-10 哈佛学院校长同事会 Method for producing stem cell-derived beta cells and method for using same
AU2016228894B2 (en) 2015-03-11 2021-03-04 Ccs Ventures Limited Pancreatic endocrine progenitor cell therapies for the treatment of obesity and Type 2 diabetes (T2D)

Also Published As

Publication number Publication date
US20210053965A1 (en) 2021-02-25
ES2958118T3 (en) 2024-02-01
AU2019208634A1 (en) 2020-08-06
KR20200110338A (en) 2020-09-23
AU2019208634A2 (en) 2020-09-24
CN111630052B (en) 2023-04-18
CA3088968C (en) 2023-10-17
EP3741757A4 (en) 2021-11-03
EP3741757B1 (en) 2023-07-26
TWI818948B (en) 2023-10-21
EP3741757A1 (en) 2020-11-25
CA3088968A1 (en) 2019-07-25
TW201938156A (en) 2019-10-01
JPWO2019142883A1 (en) 2021-01-14
US11530211B2 (en) 2022-12-20
JP7359697B2 (en) 2023-10-11
CN111630052A (en) 2020-09-04
IL276125A (en) 2020-08-31
WO2019142883A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
DK3793565T3 (en) Mcl-1-inhibitorer
DK3467457T3 (en) Vibrationssensor
DK3759096T3 (en) Cd73-inhibitorer
CA185383S (en) Casque
PL3810587T3 (en) Substituted alkoxypyridinyl indolsulfonamides
CA185384S (en) Casque
CA185382S (en) Casque
CA185385S (en) Casque
DK3773537T3 (en) Stat3-hæmmere
DK3768830T3 (en) Cancerterapi
IL283990A (en) Substituted oxopyridine derivatives
DK3613739T3 (en) Integrin-antagonister
DK3554057T3 (en) Audioheadsetsystem
DK3753395T3 (en) Indvendigt luftstyringssystem
CA184989S (en) Uroflowmeter
DK3633783T3 (en) Universal-powerbank
IL279938A (en) Spirochromane derivatives
CA184992S (en) Uroflowmeter
IL290964A (en) 2-aminoquinazolinone derivative
PL3796975T3 (en) Sulfonylaminobenzamide derivatives
DK3768906T3 (en) Træmodul
DK3650069T3 (en) Trakeostomiventil
SG11202007979UA (en) Dihydrochromene derivative
SG11202006837XA (en) Dihydroindolizinone derivative
DK3570498T3 (en) Adaptivt hvac-styresystem